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A B S T R A C T
To evaluate the efficacy of the pneumatic displacement of the submacular haemorrhage combined with the intravi-
treal injection of the tissue plasminogen activator. We present a retrospective clinical case series of nine eyes of nine pa-
tients that were treated with the intravitreal injection of the tissue plasminogen activator and expansile gas for the
submacular haemorrhage due to the age related macular degeneration. We evaluated visual acuities and complications.
Selected patients were additionally treated with the intravitreal bevacizumab injections after the procedure. Mean post-
operative followup was 19 weeks. Four (4/9) eyes (44%) received additional treatment with the intravitreal bevacizumab
during the postoperative period. Statistical analysis was performed using the Student’s paired t-test. The mean visual
acuity was 1.77 logMAR preoperatively and 1.06 logMAR postoperatively. After the surgery, 4 or more Snellen lines were
gained in 7/9 eyes (78%). The improvement of the visual acuity postoperatively was statistically significant (p = 0.002).
In 2/9 eyes (22%) the visual acuity did not get better after the procedure. We observed no complications during the follow
up period. In our case series, pneumatic displacement of the submacular haemorrhage with the use of the intravitreal tis-
sue plasminogen activator (with or without additional bevacizumab treatment in the selected cases) turned out to be an
effective and safe method leading to the improvement of the visual acuity in the majority of cases. To maximise the treat-
ment success, prompt referral to the retinal surgeon is imperative.
Key words: submacular haemorrhage, age related macular degeneration, pneumatic displacement, tissue plasmino-
gen activator, bevacizumab, visual acuity
Introduction
The most common cause of submacular haemorrhage
is bleeding from the choroidal neovascularisation associ-
ated with the age related macular degeneration (AMD).
It can also arise in the context of the posterior segment
trauma, pathological myopia, ruptured central retinal ar-
tery macroaneurism, polipoidal choroidal vasculopathy,
angioid streaks, ocular histoplasmosis and systemic dis-
eases such as coagulopathy1.
If the haemorrhage involves the fovea, loss of vision is
profound and progressive1–3. The blood clot will mechani-
cally damage the photoreceptors and prevent the normal
metabolic support to the elevated outer retina. In a few
days, toxic iron compounds will irreversibly damage the
photoreceptors. Therefore, it is sensible that appropriate
treatment procedures should be started without delay.
The first successful surgical interventions for subma-
cular haemorrhage with vitrectomy, subretinal injection
of the tissue plasminogen activator (t-PA) and retino-
tomy assisted clot removal were described in the early
1990’s4–6. In recent years less invasive treatment ap-
proaches with the intravitreal t-PA and/or gas injections
without vitrectomy have been described7–17.
During these procedures t-PA is injected into the vit-
reous and partially enters the subretinal space where
thrombolysis is induced. Injected gas bubble (and appro-
priate positioning) will then apply pressure over the
macular area and cause the thrombolysed blood clot to
dislocate away from the macula towards the periphery.
Possible complications of this method include retinal
t-PA toxicity, intraocular pressure rise, retinal detach-
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ment, endophthalmitis, uveitis, haematovitreous and ca-
taract induction18–20.
Most recently, additional treatment with antibodies
against the vascular endothelial growth factor (anti-
-VEGF) has been shown to improve the visual outcome in
subretinal haemorrhages with active choroidal neovascu-
larization21–24. Intravitreal application of anti-VEGF could
prevent progression of choroidal neovascularisation and
submacular haemorrhage recurrence.
Methods
We present a retrospective clinical case series of nine
eyes of nine patients that were treated at the Eye Hospi-
tal, University Clinical Centre, Ljubljana, Slovenia, be-
tween January 2007 and October 2011. The data were
derived from the medical records. The patients ranged in
age from 67 to 84 years. Two of them were male and
seven were female. All of them suffered from submacular
haemorrhage and were treated with the intravitreal in-
jection of t-PA and expansile gas.
They were referred to our hospital as soon as a few
hours after the onset of the vision loss and as late as 60
days after the vision loss.
On the day of presentation, patients were prepared
according to the procedure protocol in the operating
theatre. First, 50 micrograms of t-PA were injected intra-
vitrealy under the topical anesthesia. After a two-hour
period of the supine bed rest, 0.3 ccm of SF6 gas was then
injected intravitrealy. After the procedure, patients were
encouraged to the greatest possible time of face-down po-
sitioning for the next three days.
They were appointed to the regular follow up visits
one week and four weeks after the procedure, and elec-
tively thereafter. We evaluated visual acuities (VA) and
complications. For the statistical analysis, VA at presen-
tation and four weeks after the procedure were com-
pared. Statistical analysis using the Student’s paired
t-test was performed.
Selected patients with active choroidal neovasculari-
sation and without significant macular fibrosis as shown
on subsequent fluorescein angiography were additionally
treated with the intravitreal bevacizumab injections in
the weeks after the procedure.
Results
The results and patients’ characteristics are shown in
Table 1.
The mean age of patients included in our study was
74,78 years, seven of them were female and two were
male. In five eyes the hemorrhage had occurred in the
right eye and in four eyes the left eye was affected. Pa-

















1. CA 70 F L 1.60 3 0.40 1.20
2. NI 80 F L 1.60 7 1.60 0.00
3. ZB 82 F R 3.00 4 2.00 1.00 bevacizumab
4. DF 67 M R 1.60 3 0.50 1.10 bevacizumab
5. BM 67 F R 0.80 4 0.40 0.40 bevacizumab
6. ZJ 75 F L 0.70 7 0.30 0.40
7. PL 79 F L 3.00 6 1.60 1.40
8. JP 84 F R 2.00 60 2.00 0.00
9. ZK 69 M R 1.60 1 0.70 0.90 bevacizumab
VA – visual acuity
Fig. 1. Patient No. 2: at presentation, 4 weeks post procedure, 40
weeks post procedure.
Fig. 2. Patient No. 3: at presentation, 4 weeks post procedure, 34
weeks post procedure.
Fig. 3. Patient No. 4: at presentation, 1 week post procedure, 27
weeks post procedure.
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tients presented to our clinic as early as a few hours and
as late as two months after the hemorrhage had occurred.
VA before the procedure ranged form 0,7 logMAR to 3
logMAR and the mean VA was 1.77 (±0.81) logMAR. Af-
ter the procedure, displacement of submacular haemor-
rhage from the fovea centralis was achieved in seven of
nine eyes. Mean postoperative followup lasted 19 weeks.
The range of VA postoperatively was from 0.3 logMAR to
2 logMAR with a mean of 1.06 (±0.73) logMAR. Mean
improvement of the VA turned out to be 0.71 (±0.52)
logMAR, or more than 4 lines according to the decimal
VA expression system. Postoperatively, improvement of
the VA was achieved in 7/9 eyes (78%) (Graph 1). The im-
provement was statistically significant (p = 0.002). How-
ever, in 2/9 eyes (22%) no gain in the VA was detected. We
observed no complications of the procedure during the
follow up period.
Additionally, 4/9 eyes (44%) received supplementary
treatment with intravitreal bevacizumab during the
postoperative period.
Discussion
Multiple treatment possibilities have been proposed
for the treatment of the submacular haemorrhage duo to
the AMD: observation, anti-VEGF injections, photodyna-
mic therapy, vitrectomy with or without t-PA, pneumatic
displacement with or without t-PA, RPE patch surgery
and macular translocation22,25,26. There remains no con-
sensus on the optimal treatment26.
The procedure we performed has been well described
in the literature with most eyes achieving improvement
of the visual function7–17. In 7/9 eyes of the patients un-
der the examination, the gain in the VA was observed, as
well. Moreover, the procedure is minimally invasive and
can be managed under the topical anesthesia. On the
other hand, in 2/9 eyes no improvement of the VA was ob-
served. This was the consequence of the scar tissue for-
mation under the retina in the macular area.
In our case series, no eyes had VA better than 20/100
before the procedure. After the surgery VA 20/60 or
better was achieved in four eyes (44%). We believe that
this moderate improvement in vision is significant since
these patients are at risk of the vision loss to the fellow
eye due to the AMD.
The value of the early intervention is especially im-
portant in the modern age of the anti-VEGF therapy. The
possibility to treat the underlying choroidal neovascu-
larisation offers further potential for the visual rehabili-
tation if the haemorrhage is managed as soon as possible.
However, it has to be taken into account, that the
number of patients included in the study was small. To
get more representative findings, the group of examinees
should be enlarged.
Conclusion
In our case series, pneumatic displacement of the
submacular haemorrhage with the use of the intravitreal
t-PA (with or without additional bevacizumab treatment
in selected cases) turned out to be an effective and safe
method leading to the improvement of the VA in the ma-
jority of cases.
To maximise the chances for the treatment success,
prompt referral to the retinal surgeon is imperative.















Graph 1. Relationship between the patients’ visual acuities at pre-
sentation and 4 weeks after the procedure.
VPRE – visual acuity at presentation
VPOST- visual acuity 4 weeks after the procedure
Fig. 4. Patient No. 8: at presentation, 1 week post procedure, 9
weeks post procedure.
Fig. 5. Patient No. 9: at presentation, 1 week post procedure, 9
weeks post procedure.
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TRETMAN SUBMAKULARNOG KRVARENJA U PACIJENATA SA NEOVASKULARNOM
MAKULARNOM DEGENERACIJOM-AMD
S A @ E T A K
Razmatra se efikasnost primjene zraka i intravitralne aplikacije-plazminogen aktivatora, na stanje mre`nice, devet
o~iju u devet pacijenata. U ovoj aplikaciji analiziraju se mogu}e komplikacije i stanje vida. Tako|er se razmatra efikas-
nost intravitrealne aplikacije bevacizumab, nakon ovih primjenjenih metoda u vremenu od devetnaest tjedana. Analiza
o{trine vida bila je preoperativno 1,77 logMAR, a postoperativno 1,06 logMAR, {to je statisti~ki zna~ajno. U toku ovog
postupka nisu zabilje`ene komplikacije.
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